Search | Page 14 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

    For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02158936 ...

    Clinical Trial last updated 04/27/2016 - 1:28pm.

  2. Specialized technique effective in identifying chromosomal abnormalities, improving prognosis for MDS

    ... Abstract # 6521 To date, the most widely used prognostic classification system for myelodysplastic syndrome (MDS) is the International Prognostic Scoring System (IPSS). The first IPSS was derived ...

    Research Review last updated 05/02/2016 - 9:31am.

  3. Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

    ... syndrome either intermediate 1 or 2, or high risk by the International Prognostic Scoring System Chronic myelogenous leukemia (CML) in ...

    Clinical Trial last updated 05/02/2016 - 2:07pm.

  4. What is My Doctor thinking?: MDS Classification, IPSS and IPSS-R Scoring Systems for MDS

    ... The International Prognostic Scoring System (IPSS) is a classification tool used by doctors to ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  5. Myelodysplastic Syndromes are a collection of diseases with common, but also different characteristics

    ... of the disease.  The latter is provided by the International Prognostic Scoring System (IPSS).  The newest version of IPSS classifies ...

    Research Review last updated 05/02/2016 - 9:22am.

  6. Sapacitibine shows promise for high-risk MDS patients

    ... be based on the patient’s age, performance status, and International Prognostic Scoring System (IPSS and IPSS-Revised) subgroup classification. ...

    Research Review last updated 05/02/2016 - 9:30am.

  7. Options for MDS patients beyond HMAs

    ... azacytidine and decitabine , were approved for International Prognostic Scoring System (IPSS) intermediate-2 and high-risk MDS in 2004 ...

    Research Review last updated 05/02/2016 - 9:09am.

  8. Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

    ... azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high ...

    Clinical Trial last updated 04/29/2016 - 12:55pm.

  9. A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

    ... (MDS) patients, as evaluated by the International Prognostic Scoring System -Revised (IPSS-R). Eligible participants will either have ...

    Clinical Trial last updated 04/27/2016 - 9:57am.

  10. A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation (AML)

    ... as ≥ 10% peripheral blood or marrow blasts and international Prognostic Scoring System [IPSS] score ≥ 2) and relapsed or refractory to ...

    Clinical Trial last updated 05/09/2016 - 4:09pm.